FDA Brief

Warning letters Devices

FDA warning letter to

ZIIP, Inc.

High riskIssued May 22Posted Jul 14Center for Devices and Radiological Health

FDA warns ZIIP over quality-system violations and unapproved marketing of HALO 2.0, DOT, and gels.

What happened

FDA inspected ZIIP’s Pleasant Hill, CA facility from January 5 to January 12, 2026, and reviewed the website ziipbeauty.com. FDA found violations of the Quality System regulation (FDA’s manufacturing quality rules), including risk and complaint handling problems tied to reports of devices smoking, burning, or melting, and found Halo 2.0, DOT, and gels marketed without required clearances. FDA said ZIIP’s responses dated February 3 and May 15, 2026 were not adequate.

What FDA found

  1. FDA says design verification did not show that design outputs met design inputs, with missing raw data, an undocumented firmware build, and no formal review of an external test report.

    21 CFR 820.30(f)
  2. FDA says ZIIP’s risk analysis did not reflect complaints of overheating, smoking, burning, or melting and did not properly validate alternative gels.

    21 CFR 820.30(g)
  3. FDA says CAPAs were closed without required effectiveness checks or evidence that the fixes worked.

    21 CFR 820.100(a)
  4. FDA says app, firmware, and charging-port plug changes were made without proper documentation, review, or verification/validation.

    21 CFR 820.30(i)
  5. FDA says 26 HALO complaints lacked investigation records or a documented reason not to investigate.

    21 CFR 820.198(a)
  6. FDA says Halo 2.0, DOT, and the gels are marketed for new uses without required premarket approval/clearance and without 510(k) notification.

    section 501(f)(1)(B), section 502(o), and section 510(k) of the Act

What FDA wants

FDA tells ZIIP that its responses are not adequate and that it must correct the cited quality-system, complaint, CAPA, design, and premarket violations; specific response deadlines are redacted in the letter.

Who should pay attention

  • medical device companies with app and firmware design changes
  • quality teams that use complaint data in risk analysis
  • aesthetic device brands making unapproved claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  2. Pro-Optics, LLC

    FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.

    Medium
  3. Unilam Co., LTD

    Unilam Co., LTD's UV sunlamps violate quality-system and radiation-safety testing rules, FDA says.

    High risk
  4. Nipro Renal Solutions USA, Corporation

    Nipro Renal Solutions USA released hemodialysis dialysate lots with out-of-spec endotoxin (bacterial toxin) and had widespread quality-system failures, FDA says.

    High risk